Abstract:Adiponectin receptor agonists have recently been reported to protect against glomerular inflammation and injury during obesity. Nevertheless, the molecular mechanism underlying their protective action against obesity-related glomerulopathy (ORG) remains poorly understood. Given the implication of ceramide signaling pathway in the pathogenesis of ORG, the present study tested whether adiponectin receptor agonists target lysosomal acid ceramidase (AC) to inhibit NLRP3 inflammasome activation and glomerular injury during obesity. Confocal microscopy showed that NLRP3 inflammasome activation induced by visfatin, a pro-inflammatory adipokine, in murine podocytes was remarkably attenuated by adiponectin. Also, it was found that adiponectin significantly inhibited visfatin-induced formation of multivesicular bodies (MVBs) containing IL-1β in podocytes. Such inhibitory effect of adiponectin was abolished by AC inhibitors (carmofur and ARN14974) but mimicked by genistein (AC inducer) or MCC950 (NLRP3 inflammasome inhibitor). By nanoparticle tracking analysis, we measured exosomes released from podocytes in different groups, which have been reported to mediate the secretion of NLRP3 inflammasome products to extracellular space to activate inflammatory response. Visfatin-induced elevation of exosome release from podocytes was remarkably suppressed by adiponectin. This action of adiponectin was blocked by AC inhibitors but mimicked by genistein. In vivo, we showed that high-fat diet-induced T cell infiltration in glomeruli was exaggerated by podocyte-specific Smpd1 gene (gene code of acid sphingomyelinase) overexpression in Smpd1trg/Podocre mice compared to WT/WT mice. However, intraperitoneal injection of AdipoRon, a synthetic adiponectin receptor agonist, significantly decreased obesity-induced glomerular inflammatory response in both WT/WT and Smpd1trg/Podocre mice. Such anti-inflammatory effect of AdipoRon was prevented by co-treatment with carmofur. Moreover, podocyte-specific Smpd1 gene overexpression amplified HFD-induced podocyte injury, proteinuria, and glomerular sclerosis in Smpd1trg/Podocre mice compared to control littermates. These pathological changes were prevented by AdipoRon, and the effect of AdipoRon was reversed by carmofur. Taken together, our findings suggest that activation of AC signaling pathway mediates the protective action of adiponectin receptor agonists against glomerular inflammation and injury in ORG. This study was supported by NIH grants DK054927 and DK120491. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Adiponectin inhibits palmitic acid-induced NLRP3 inflammasome activation in hepatocytes through AMPK-JNK/ErK1/2-NFκB/ROS signaling pathways

Adiponectin Inhibits NLRP3 Inflammasome Activation in Nonalcoholic Steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS Signaling Pathways

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway

Retraction Note: Adiponectin Deficiency Rescues High-Fat Diet-Induced Hepatic Injury, Apoptosis and Autophagy Loss Despite Persistent Steatosis

Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress

Acid Ceramidase as a Novel Target for Adiponectin Receptor Agonist to Abrogate NLRP3 Inflammasome Activation and Glomerular Injury during Obesity

NLRP3 inflammasome mediate palmitate-induced endothelial dysfunction

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice

Effect of adiponectin on the expression of NLRP3 inflammasome and inflammatory factors in LPS-induced RAW264.7 macrophage

Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis

The effect of adiponectin on mediating inflammation by regulating mitochondrial autophagy through AMPK pathway

AdipoRon prevents myostatin‐induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line

STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease

Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice

Adiponectin plays a protective role in caerulein-induced acute pancreatitis in mice fed a high-fat diet

A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet

The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation